CY1111945T1 - Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1) - Google Patents

Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1)

Info

Publication number
CY1111945T1
CY1111945T1 CY20111100738T CY111100738T CY1111945T1 CY 1111945 T1 CY1111945 T1 CY 1111945T1 CY 20111100738 T CY20111100738 T CY 20111100738T CY 111100738 T CY111100738 T CY 111100738T CY 1111945 T1 CY1111945 T1 CY 1111945T1
Authority
CY
Cyprus
Prior art keywords
compounds
subunit receptor
fusion compounds
inhibit vanilloid
receptor
Prior art date
Application number
CY20111100738T
Other languages
English (en)
Inventor
Arthur Gomtsyan
Erol K Bayburt
Chih-Hung Lee
John R Koenig
Robert Schmidt
Kirill Lukin
Gilles Chambournier
Margaret Hsu
Robert M Leanna
Russel D Cink
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111945(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/459,925 external-priority patent/US7015233B2/en
Priority claimed from US10/864,068 external-priority patent/US7375126B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1111945T1 publication Critical patent/CY1111945T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Materials For Photolithography (AREA)

Abstract

Η παρούσα εφεύρεση γνωστοποιεί νέες ενώσεις του γενικού τύπου (I), ή ένα φαρμακευτικώς αποδεκτό άλας αυτών (στις οποίες X1-Χ5, R5-R8b, Ζ1-Ζ2 και Αr1 ορίζονται στο παρόν), φαρμακευτικές συνθέσεις οι οποίες περιλαμβάνουν αυτές τις ενώσεις και μια διαδικασία για παρασκευή αυτών των ενώσεων. Οι ενώσεις του τύπου (I) είναι χρήσιμες για αντιμετώπιση άλγους, υπερδραστηριότητας της ουροδόχου κύστης, ουρικής ακράτειας, φλεγμονώδους υπεραλγησίας μέσω αναστολής του VR1 υποδοχέα σε θηλαστικά.
CY20111100738T 2003-06-12 2011-07-28 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1) CY1111945T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/459,925 US7015233B2 (en) 2003-06-12 2003-06-12 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en) 2003-06-12 2004-06-09 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP08166079A EP2017265B1 (en) 2003-06-12 2004-06-10 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Publications (1)

Publication Number Publication Date
CY1111945T1 true CY1111945T1 (el) 2015-11-04

Family

ID=33555102

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100044T CY1108713T1 (el) 2003-06-12 2009-01-14 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1)
CY20111100738T CY1111945T1 (el) 2003-06-12 2011-07-28 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20091100044T CY1108713T1 (el) 2003-06-12 2009-01-14 Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοϊδους υποτυπου 1 (vr1)

Country Status (20)

Country Link
EP (2) EP2017265B1 (el)
JP (2) JP4857113B2 (el)
KR (2) KR101138216B1 (el)
CN (1) CN102617464A (el)
AT (2) ATE411982T1 (el)
AU (2) AU2004247721C1 (el)
BR (1) BRPI0411116A (el)
CA (2) CA2756058A1 (el)
CY (2) CY1108713T1 (el)
DE (1) DE602004017329D1 (el)
DK (2) DK1658269T3 (el)
ES (1) ES2318308T3 (el)
IL (4) IL172457A (el)
MX (1) MXPA05013550A (el)
NZ (3) NZ590234A (el)
PL (2) PL1658269T3 (el)
PT (2) PT2017265E (el)
SI (2) SI1658269T1 (el)
TW (3) TWI366461B (el)
WO (1) WO2004111009A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
EP1824843A2 (en) 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2008523071A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド Ｍａｐキナーゼの尿素インヒビター
WO2007042906A1 (en) 2005-10-07 2007-04-19 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2007050574A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
TW200819441A (en) 2005-10-28 2008-05-01 Abbott Lab Prodrugs of compounds that inhibit TRPV1 receptor
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
JP2009534399A (ja) * 2006-04-18 2009-09-24 アボット・ラボラトリーズ バニロイド受容体サブタイプ１型（ｖｒ１）の拮抗薬およびその使用
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
CN102186836A (zh) * 2008-10-17 2011-09-14 雅培制药有限公司 Trpv1拮抗剂
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
MX2014013489A (es) * 2012-05-09 2015-02-12 Bayer Cropscience Ag 5-halogenopirazolindanil carboxamidas.
HRP20161613T1 (hr) 2012-11-13 2017-01-13 Array Biopharma, Inc. Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MY178262A (en) 2012-11-13 2020-10-07 Array Biopharma Inc Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078408A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3448519A4 (en) * 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System SIGMA RECEPTOR BINDING
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536734B (en) * 2000-07-31 2003-06-11 Clariant Int Ltd Process for manufacturing a microelectronic device
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Also Published As

Publication number Publication date
CY1108713T1 (el) 2014-04-09
IL215997A0 (en) 2011-12-29
NZ543713A (en) 2009-08-28
CA2756058A1 (en) 2004-12-23
JP4857113B2 (ja) 2012-01-18
AU2004247721A1 (en) 2004-12-23
KR20110089464A (ko) 2011-08-08
PT2017265E (pt) 2011-07-29
IL216046A0 (en) 2011-12-29
PL2017265T3 (pl) 2011-11-30
SI2017265T1 (sl) 2011-09-30
EP1658269B1 (en) 2008-10-22
IL172457A0 (en) 2006-04-10
HK1126488A1 (en) 2009-09-04
DK1658269T3 (da) 2009-01-12
CA2526872C (en) 2013-02-05
AU2010257277B2 (en) 2011-08-18
HK1093727A1 (en) 2007-03-09
IL207335A (en) 2012-02-29
PL1658269T3 (pl) 2009-08-31
DK2017265T3 (da) 2011-09-19
IL207335A0 (en) 2010-12-30
EP1658269A1 (en) 2006-05-24
DE602004017329D1 (de) 2008-12-04
JP2007500753A (ja) 2007-01-18
JP2011153148A (ja) 2011-08-11
ES2318308T3 (es) 2009-05-01
ATE411982T1 (de) 2008-11-15
KR101138216B1 (ko) 2012-09-05
TW201300361A (zh) 2013-01-01
TW200509926A (en) 2005-03-16
PT1658269E (pt) 2009-01-09
TWI366461B (en) 2012-06-21
ATE510824T1 (de) 2011-06-15
NZ578264A (en) 2011-02-25
WO2004111009A1 (en) 2004-12-23
IL172457A (en) 2011-12-29
BRPI0411116A (pt) 2006-07-18
KR101150324B1 (ko) 2012-06-13
SI1658269T1 (sl) 2009-04-30
AU2004247721B2 (en) 2011-01-20
TWI394569B (zh) 2013-05-01
CA2526872A1 (en) 2004-12-23
EP2017265A1 (en) 2009-01-21
NZ590234A (en) 2012-07-27
KR20060058769A (ko) 2006-05-30
AU2004247721C1 (en) 2011-12-22
MXPA05013550A (es) 2006-04-05
TW201038269A (en) 2010-11-01
EP2017265B1 (en) 2011-05-25
CN102617464A (zh) 2012-08-01
AU2010257277A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
CY1111945T1 (el) Συντηγμενες ενωσεις προς αναστολη του υποδοχεα βανιλλοειδους υποτυπου 1 (vr1)
IL173269A0 (en) Compounds for inflammation and immune-related uses
WO2006062981A3 (en) Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
TW200621232A (en) Compounds for inflammation and immune-related uses
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
SE0302324D0 (sv) Novel compounds
SE0302323D0 (sv) Novel compounds
MX2007005611A (es) Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
PT1202959E (pt) Aminobenzofenonas como inibidores de il-1-beta e tnf-alfa
WO2006113552A3 (en) Cyanoarylamines
WO2005040121A3 (en) Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2006063178A3 (en) Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
MX2007007100A (es) Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
WO2005005394A3 (en) Thiophenylaminoimidazolines as prostaglandin i2 antagonists
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
WO2006029210A3 (en) Acyclic 1,3-diamines and uses therefor
BRPI0511824A (pt) radiossensibilizador
GB0327331D0 (en) Therapeutic agents